Ratings AbbVie Inc.

Equities

Market Closed - Nyse Other stock markets 16:00:02 2025-01-17 EST			5-day change	1st Jan Change
171.56 ^USD	-1.23%		-2.06%	-3.46%

01-17	Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks	MT
01-17	Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks	MT

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
The company has a good ESG score relative to its sector, according to MSCI.

The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Analysts covering this company mostly recommend stock overweighting or purchase.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

The company is in debt and has limited leeway for investment
With an expected P/E ratio at 38.17 and 23.62 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The company's "enterprise value to sales" ratio is among the highest in the world.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.

Source: Surperformance

Source: MSCI

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Composite Fundamentals	Composite Valuation	Composite Momentum	Capi. ($)
	ABBVIE INC.				303B
	ELI LILLY AND COMPANY				653B
	JOHNSON & JOHNSON				354B
	NOVO NORDISK A/S				353B
	MERCK & CO., INC.				248B
	ROCHE HOLDING AG				234B
	ASTRAZENECA PLC				207B
	NOVARTIS AG				195B
	PFIZER, INC.				149B
	AMGEN INC.				146B
	Average				284.21B
	Weighted average by Cap.